Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002913 | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00004032 | Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | completed | Phase 1 / Phase 2 | 138 | AbbVie (prior sponsor, Abbott)INDUSTRY | 9 | Jan 18, 2013 | clinicaltrials |
| NCT00003358 | Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00335998 | Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00672295 | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | completed | Phase 1 | 11 | AA SecordOTHER | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00006357 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 91 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT01041235 | Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies | completed | Phase 1 | 29 | Azaya Therapeutics, Inc.INDUSTRY | 1 | Sep 6, 2012 | clinicaltrials |
| NCT00059618 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00877253 | Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer | completed | Phase 1 | 18 | Samyang Biopharmaceuticals CorporationINDUSTRY | 0 | Jun 12, 2012 | clinicaltrials |
| NCT00032162 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | completed | Phase 1 / Phase 2 | 63 | AGO Study GroupOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT00237627 | Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 107 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 18, 2012 | clinicaltrials |
| NCT00436657 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | completed | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 2, 2012 | clinicaltrials |
| NCT00019019 | Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas | completed | Phase 1 | 70 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00030108 | Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy | completed | Phase 1 | 30 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00036959 | ABT-751 in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 90 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00303940 | Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors | completed | Phase 1 | 26 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00064311 | Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00034281 | Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 | completed | Phase 1 | 16 | TakedaINDUSTRY | 1 | Feb 2, 2012 | clinicaltrials |
| NCT00250094 | Clinical Benefit of Topoisomerase Downregulation | completed | Phase 1 | 15 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 7, 2011 | clinicaltrials |
| NCT00051948 | TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | TelikINDUSTRY | 1 | Jul 25, 2011 | clinicaltrials |
| NCT00052065 | TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | TelikINDUSTRY | 1 | Jul 25, 2011 | clinicaltrials |
| NCT00429559 | Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma | completed | Phase 1 / Phase 2 | 31 | Hellenic Oncology Research GroupOTHER | 1 | Jul 22, 2011 | clinicaltrials |
| NCT00004177 | Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer | completed | Phase 1 / Phase 2 | 15 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00489359 | Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 86 | Eli Lilly and CompanyINDUSTRY | 5 | Jun 16, 2011 | clinicaltrials |
| NCT00750386 | Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas | completed | Phase 1 / Phase 2 | 50 | Hellenic Oncology Research GroupOTHER | 1 | May 23, 2011 | clinicaltrials |
| NCT00667641 | Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | completed | Phase 1 | 16 | University of Medicine and Dentistry of New JerseyOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT00028912 | Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00006391 | Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | NYU Langone HealthOTHER | 1 | Apr 5, 2011 | clinicaltrials |
| NCT00003297 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer | completed | Phase 1 / Phase 2 | 50 | Georgetown UniversityOTHER | 1 | Mar 24, 2011 | clinicaltrials |
| NCT00316407 | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients | completed | Phase 1 / Phase 2 | 30 | Swedish Medical CenterOTHER | 1 | Feb 18, 2011 | clinicaltrials |
| NCT00562003 | Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients(Ad5Delta24RGD) | completed | Phase 1 | 26 | University of Alabama at BirminghamOTHER | 1 | Jan 26, 2011 | clinicaltrials |
| NCT00002508 | Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors | completed | Phase 1 / Phase 2 | — | Temple UniversityOTHER | 1 | Oct 1, 2010 | clinicaltrials |
| NCT00217529 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00002977 | Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission | completed | Phase 1 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 15, 2010 | clinicaltrials |
| NCT00003080 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer | completed | Phase 1 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 15, 2010 | clinicaltrials |
| NCT00648102 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer(CDX1307-02) | completed | Phase 1 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2010 | clinicaltrials |
| NCT00709462 | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | completed | Phase 1 | 48 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2010 | clinicaltrials |
| NCT00101257 | Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 1 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2010 | clinicaltrials |
| NCT00010283 | Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00002901 | Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | completed | Phase 1 | — | City of Hope Medical CenterOTHER | 1 | Jan 13, 2010 | clinicaltrials |
| NCT00164658 | Evaluating Tools for Health Promotion and Disease Prevention | completed | Phase 1 | 8,400 | Centers for Disease Control and PreventionFED | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00465725 | A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | completed | Phase 1 | 18 | Poniard PharmaceuticalsINDUSTRY | 1 | Sep 24, 2009 | clinicaltrials |
| NCT00120939 | Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer | completed | Phase 1 | 25 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00291473 | Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers | completed | Phase 1 | 9 | Ludwig Institute for Cancer ResearchOTHER | 1 | Mar 3, 2009 | clinicaltrials |
| NCT00315861 | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | completed | Phase 1 | 15 | SCRI Development Innovations, LLCOTHER | 1 | Jan 23, 2009 | clinicaltrials |
| NCT00338026 | A Phase I Study of ECO-4601 in Patients With Advanced Cancer | completed | Phase 1 | 26 | Thallion PharmaceuticalsINDUSTRY | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00001272 | A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Jan 24, 2013source: clinicaltrials